Krystal Biotech, Inc. - 8-K Filing

Krystal Biotech reports Q3 2026 VYJUVEK revenue of $127.3 million and authorizes a $400 million share repurchase program. (Items: 2.02 Results of Operations and Financial ConditionOn November 2, 2026, Krystal Biotech, Inc, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 2, 2026, 12:07 UTC

Tickers: $KRYS

Read the full article at SEC EDGAR

Part of the story Krystal Biotech, Inc. - 10-Q Filing (14 articles)

More Regulatory news

CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
RF Acquisition Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 14:04 UTC
ORASURE TECHNOLOGIES INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Rocket Companies, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:03 UTC
Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC